{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:13:51Z","timestamp":1790745231152,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003669","name":"Korea Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2019.12.048","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T12:12:37Z","timestamp":1578053557000},"page":"1586-1588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of the protective efficacy of recombinant protective antigen vaccine (GC1109)-immunized human sera using passive immunization in a mouse model"],"prefix":"10.1016","volume":"38","author":[{"given":"Su Kyoung","family":"Jo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Eun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hye","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Eun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyonggin","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myoung-don","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi-eun","family":"Rhie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.12.048_b0005","series-title":"The anthrax vaccine: is it safe? Does it work?, Washington (DC)","first-page":"180","article-title":"Anthrax vaccine manufacture","author":"Joellenbeck","year":"2002"},{"key":"10.1016\/j.vaccine.2019.12.048_b0010","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/j.1365-2672.2007.03391.x","article-title":"A study of the physiology of Bacillus anthracis Sterne during manufacture of the UK acellular anthrax vaccine","volume":"103","author":"Charlton","year":"2007","journal-title":"J Appl Microbiol"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2019.12.048_b0015","doi-asserted-by":"crossref","first-page":"D28","DOI":"10.1016\/j.vaccine.2009.08.102","article-title":"Advances in the development of next-generation anthrax vaccines","volume":"27","author":"Friedlander","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.048_b0020","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.mam.2009.08.006","article-title":"Anthrax vaccination strategies","volume":"30","author":"Cybulski","year":"2009","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.vaccine.2019.12.048_b0025","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.femsim.2005.05.008","article-title":"Expression and secretion of the protective antigen of Bacillus anthracis in Bacillus brevis","volume":"45","author":"Rhie","year":"2005","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2019.12.048_b0030","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1016\/j.vaccine.2019.05.057","article-title":"Immunogenicity and safety of a novel recombinant protective antigen anthrax vaccine (GC1109), a randomized, single-blind, placebo controlled phase II clinical study","volume":"37","author":"Kang","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.048_b0035","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1016\/j.vaccine.2008.05.068","article-title":"An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals","volume":"26","author":"Hewetson","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.048_b0040","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1128\/iai.51.3.795-800.1986","article-title":"Differences in susceptibility of inbred mice to Bacillus anthracis","volume":"51","author":"Welkos","year":"1986","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.12.048_b0045","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/0264-410X(95)00139-R","article-title":"Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs","volume":"13","author":"Ivins","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.048_b0050","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints12","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.12.048_b0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biologicals.2003.09.003","article-title":"Validation of the anthrax lethal toxin neutralization assay","volume":"32","author":"Hering","year":"2004","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2019.12.048_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v012.i05","article-title":"Bioassay analysis using R","volume":"12","author":"Ritz","year":"2005","journal-title":"J Stat Softw"},{"key":"10.1016\/j.vaccine.2019.12.048_b0065","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.vaccine.2006.05.044","article-title":"Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial","volume":"24","author":"Gorse","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.048_b0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4161\/hv.3.5.4459","article-title":"Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults","volume":"3","author":"Campbell","year":"2007","journal-title":"Hum Vaccin"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19317001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19317001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:41:30Z","timestamp":1759401690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19317001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X19317001"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the protective efficacy of recombinant protective antigen vaccine (GC1109)-immunized human sera using passive immunization in a mouse model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}